Zilico Makes Moves in Australian Market

07 May 2014

Zilico Ltd (winner of the 2014 Medilink UK Partnership with the NHS Award) has made two major announcements which will see the company’s cervical cancer diagnostics product – ZedScan – start being sold in to the Australian healthcare market.

ZedScan has obtained approval from Therapeutic Goods Administration (TGA) - the regulatory body for therapeutic goods (including medicines, medical devices, gene technology, and blood products) in Australia.

TGA approval for ZedScan means that is now listed on the register of medical devices and can be sold to the Australian Market.

TGA approval is also accepted by other countries including Singapore and is viewed positively by regulatory authorities where there is a Mutual Recognition Agreement in place such as New Zealand.

In conjunction with TGA approval, Zilico has also announced that the company has signed up its Australian distributor for ZedScan – Endotherapeutics Pty Limited.

Endotherapeutics specialises in the sales, marketing, regulatory approval and distribution of leading medical devices for various healthcare segments.

Adam Srejber, Business Development and Operations Manager at Endotherapeutics, said: “We are very excited about launching ZedScan in Australia.

“The device has the potential to make a significant impact on how women are managed within the cervical cancer pathway and we’re looking forward to presenting it to healthcare organisations across the country.”

ZedScan improves the accuracy of colposcopy, enabling clinicians to confidently identify and treat women with severe cervical abnormalities at first visit and minimising patient anxiety.

The ability to pin-point the location of pre-cancerous lesions in real time also leads to a reduction in the number of biopsies required lessening any associated discomfort experienced by the women.

Chris Harris, Commercial Director of Zilico Ltd, said: “This is another milestone in marketing ZedScan and we are very pleased to have achieved regulatory approval whilst simultaneously signing up a partner with substantial experience to sell and market a new innovative device.”